The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study

Vitetta, Luis, Coulson, Samantha, Beck, Shoshannah L., Gramotnev, Helen, Du, Sharon and Lewis, Sophie (2013) The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study. Complementary Therapies in Medicine, 21 3: 164-171. doi:10.1016/j.ctim.2012.12.006


Author Vitetta, Luis
Coulson, Samantha
Beck, Shoshannah L.
Gramotnev, Helen
Du, Sharon
Lewis, Sophie
Title The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study
Journal name Complementary Therapies in Medicine   Check publisher's open access policy
ISSN 0965-2299
1873-6963
Publication date 2013-06
Year available 2013
Sub-type Article (original research)
DOI 10.1016/j.ctim.2012.12.006
Open Access Status
Volume 21
Issue 3
Start page 164
End page 171
Total pages 8
Place of publication Churchill Livingstone
Publisher London, United Kingdom
Collection year 2014
Language eng
Formatted abstract
Objective: The aim of the study was to determine if a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) combination was effective in reducing the number of colds and in turn improving symptom recovery in a cohort of males and females that reported frequently contracting a cold.

Design: A double blind randomized placebo-controlled clinical trial.

Setting: One-hundred and twenty-six participants matched by age, BMI, dietary and physical parameters with self-reported frequent upper respiratory tract symptoms and infections were randomly assigned to receive 600 mg of Lf/IgF or a placebo daily for 90 days.

Main outcome measures and results: A total of 90 participants (47 receiving the active and 43 placebo) completed the 90 day trial and 15 completed 45 days participation (6 in the active and 9 in the placebo group). The total number of colds recorded over the study period was 48 for the treatment group versus 112 for the placebo group (p < 0.001). The significant trend was retained when the data was corrected for medications returned (p < 0.001) and for guessing treatment allocations (p < 0.001). Non-parametric analysis demonstrated that the total number of cold-associated symptoms reported by participants that received Lf/IgF was significantly less than those in the placebo group (p < 0.05). Also, total days sick with a cold and cold severity were reduced over the clinical trial period for Lf/IgF over placebo, but the trend was not significant.

Conclusions: These findings demonstrate that the Lf/IgF combination significantly decreased the incidence of colds and the cumulative number of cold-related symptoms over placebo. This therapeutic combination may be indicated for the prevention of colds and its most common symptoms in the general population when administered as a preventative supplement.
Keyword Bovine lactoferrin
Whey protein immunoglobulins
Clinical efficacy
Common cold
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 19 Feb 2013, 19:34:23 EST by Dr Luis Vitetta on behalf of Medicine - Princess Alexandra Hospital